Sansure Biotech, Inc. (688289.SH) Latest Company News

Oct 28, 2026, 10:46 UTC
Sansure Biotech reported first-nine-month 2026 revenue of 1.252 billion yuan, up 0.66% year over year, and net profit of 104 million yuan, down 45.62%.
Source:
- finance.sina.cn
Oct 28, 2026, 10:46 UTC
Sansure Biotech reported third-quarter 2026 revenue of 418 million yuan, up 11.33% year over year, and net profit of 6.0311 million yuan, down 78.91%.
Source:
- finance.sina.cn
Oct 12, 2026, 11:58 UTC
China's National Medical Products Administration granted Sansure Biotech's nucleic acid test kit for parainfluenza virus, human rhinovirus, adenovirus and Mycoplasma pneumoniae a Class III in-vitro diagnostic medical-device registration certificate.
Source:
- finance.sina.cn
Sep 15, 2026, 15:11 UTC
Sansure Biotech's board secretary Huang Qiang resigned for personal reasons, and chairman Dai Lizhong will temporarily assume the board secretary duties.
Source:
- finance.ifeng.com
Aug 26, 2026, 11:21 UTC
Sansure Biotech proposed a cash dividend of 2.65 yuan per 10 shares (tax inclusive), totaling 151 million yuan, subject to shareholder approval.
Source:
- finance.sina.cn
Aug 26, 2026, 11:21 UTC
Sansure Biotech announced its first-half 2026 results: revenue of 834 million yuan, down 3.95% year-on-year; net profit attributable to shareholders of 98.0173 million yuan, down 39.76%; non-recurring net profit of 53.7043 million yuan, down 60.48%.
Source:
- finance.sina.cn
Aug 18, 2026, 11:11 UTC
Sansure Biotech announced that its dengue and chikungunya virus nucleic acid detection kit received a medical device registration certificate from China's National Medical Products Administration, valid until August 16, 2031.
Source:
- finance.sina.cn

688289.SH

Sansure Biotech reported first-nine-month 2026 revenue of 1.252 billion yuan, up 0.66% year over year, and net profit of 104 million yuan, down 45.62%.

Sansure Biotech reported third-quarter 2026 revenue of 418 million yuan, up 11.33% year over year, and net profit of 6.0311 million yuan, down 78.91%.

China's National Medical Products Administration granted Sansure Biotech's nucleic acid test kit for parainfluenza virus, human rhinovirus, adenovirus and Mycoplasma pneumoniae a Class III in-vitro diagnostic medical-device registration certificate.

Sansure Biotech's board secretary Huang Qiang resigned for personal reasons, and chairman Dai Lizhong will temporarily assume the board secretary duties.

Sansure Biotech proposed a cash dividend of 2.65 yuan per 10 shares (tax inclusive), totaling 151 million yuan, subject to shareholder approval.

Sansure Biotech announced its first-half 2026 results: revenue of 834 million yuan, down 3.95% year-on-year; net profit attributable to shareholders of 98.0173 million yuan, down 39.76%; non-recurring net profit of 53.7043 million yuan, down 60.48%.

Sansure Biotech announced that its dengue and chikungunya virus nucleic acid detection kit received a medical device registration certificate from China's National Medical Products Administration, valid until August 16, 2031.